Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2020

01-11-2020 | Glioblastoma | Topic Review

The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline

Authors: José E. Velázquez Vega, Daniel J. Brat, Timothy C. Ryken, Jeffrey J. Olson

Published in: Journal of Neuro-Oncology | Issue 2/2020

Login to get access

Abstract

Target Population

These recommendations apply to adult patients with newly diagnosed or suspected glioblastoma (GBM)

Question

For adult patients with newly diagnosed GBM does testing for Isocitrate Dehydrogenase 1 or 2 (IDH 1/2) mutations afford benefit beyond standard histopathology in providing accurate classification and outcome prognostication?
Level III IDH 1/2 mutational status by immunohistochemistry (IHC) and/or sequencing is suggested for classification and prognostic information.
Level III Non-canonical IDH 1/2 mutations are very rare in patients aged 55 or older and universal testing of variant mutations by sequence analysis is not suggested for this age range.

Question

For adult patients with lower grade infiltrating astrocytomas (WHO grades II and III) can the IDH-wildtype status designation supersede histopathology to predict prognosis and biologic relevance to eventual behavior as a GBM?
Level III The designation of infiltrating astrocytomas (WHO grades II and III) as IDH-wildtype is not suggested as sufficient for a higher grade designation alone.
Level III It is suggested that IDH-wildtype WHO grades II and III astrocytomas be tested for molecular-genetic alterations typical of IDH-wildtype GBM such as EGFR amplification, gain of chromosome 7/loss of chromosome 10 and TERT-p mutation to substantiate prediction of behavior similar to IDH-wildtype glioblastoma.
Level III It is suggested that a diagnosis of diffuse astrocytic glioma, IDH-wildtype, with molecular features of GBM, WHO grade IV be rendered for infiltrating astrocytomas that lack histologic criteria of GBM but harbors molecular-genetic alterations of IDH-wildtype glioblastoma.

Question

For adult patients with newly diagnosed infiltrating glioma arising in the midline does testing for H3-K27M mutations provide information beyond that gained by histopathology for accurate classification and outcome prognostication?
Level III It is suggested that infiltrating gliomas arising in midline anatomic locations be tested for the H3-K27M mutation as they tend to exhibit WHO grade IV behavior even if they lack histologic criteria for glioblastoma.
Literature
1.
Burger PC, Scheithauer BW, Lee RR, O'Neill BP (1997) An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions. Cancer 80(11):2040–2046PubMedCrossRef
2.
Burger PC, Nelson JS, Boyko OB (1998) Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. Arch Pathol Lab Med 122(7):620–632PubMed
3.
Burger PC, Nelson JS, Boyko OB (1998) Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. Arch Pathol Lab Med 122(7):609–619PubMed
4.
Perry A, Brat DJ (2018) Practical surgical neuropathology: a diagnostic approach, 2nd edn. Elsevier, Philadelphia
5.
Love S, Budka H, Ironside JW, Perry A (2015) Greenfield's neuropathology, 9th. CRC Press, Boca Raton
6.
Kleinschmidt-DeMasters B, Rodríguez FJ, Tihan T (2016) Diagnostic pathology. Neuropathology, 2nd edn. Elsevier, Philadelphia, PA
7.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WKE (2016) WHO classification of tumours of the central nervous system (revised 4th edition). International Agency for Research on Cancer (IARC), Lyon
8.
Brat DJ, Prayson RA, Ryken TC, Olson JJ (2008) Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 89(3):287–311PubMedCrossRef
9.
Bullock R, Chesnut RM, Clifton G et al (1996) Guidelines for the management of severe head injury. Brain Trauma Foundation. Eur J Emerg Med 3(2):109–127PubMedCrossRef
10.
Brat DJ, Verhaak RG et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 372(26):2481–2498PubMedCrossRef
11.
12.
13.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153PubMedPubMedCentralCrossRef
14.
Ward PS, Cross JR, Lu C et al (2012) Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31(19):2491–2498PubMedCrossRef
15.
Dang L, Yen K, Attar EC (2016) IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 27(4):599–608PubMedCrossRef
16.
Xu W, Yang H, Liu Y et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1):17–30PubMedPubMedCentralCrossRef
17.
Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522PubMedPubMedCentralCrossRef
18.
19.
Lu C, Ward PS, Kapoor GS et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483(7390):474–478PubMedPubMedCentralCrossRef
20.
21.
Wiestler B, Capper D, Sill M et al (2014) Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128(4):561–571PubMedCrossRef
22.
23.
Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28(3):177–183PubMedCrossRef
24.
Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C (2015) IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 6(30):30295–30305PubMedPubMedCentralCrossRef
25.
Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772PubMedCrossRef
26.
Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):829–848PubMedCrossRef
27.
Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474PubMedCrossRef
28.
29.
Gierke M, Sperveslage J, Schwab D et al (2016) Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. J Cancer Res Clin Oncol 142(1):89–100PubMedCrossRef
30.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602PubMedCrossRef
31.
Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729PubMedCrossRef
32.
Ellison DW (2015) Multiple molecular data sets and the classification of adult diffuse gliomas. N Engl J Med 372(26):2555–2557PubMedCrossRef
33.
Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245–254PubMedCrossRef
34.
Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118(5):599–601PubMedCrossRef
35.
Brandner S, von Deimling A (2015) Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol 41(6):694–720PubMedCrossRef
36.
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820PubMedCrossRef
37.
Chen L, Voronovich Z, Clark K et al (2014) Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16(11):1478–1483PubMedPubMedCentralCrossRef
38.
DeWitt JC, Jordan JT, Frosch MP et al (2017) Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro Oncol 19(12):1640–1650PubMedPubMedCentralCrossRef
39.
Robinson C, Kleinschmidt-DeMasters BK (2017) IDH1-mutation in diffuse gliomas in persons age 55 years and over. J Neuropathol Exp Neurol 76(2):151–154PubMed
40.
Figarella-Branger D, Bouvier C, de Paula AM et al (2012) Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. J Neurooncol 110(2):205–213PubMedCrossRef
41.
Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164(3):550–563PubMedPubMedCentralCrossRef
42.
Cryan JB, Haidar S, Ramkissoon LA et al (2014) Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget 5(18):8083–8092PubMedPubMedCentralCrossRef
43.
Killela PJ, Pirozzi CJ, Reitman ZJ et al (2014) The genetic landscape of anaplastic astrocytoma. Oncotarget 5(6):1452–1457PubMedCrossRef
44.
Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126(3):443–451PubMedCrossRef
45.
Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129(1):133–146PubMedCrossRef
46.
Olar A, Wani KM, Alfaro-Munoz KD et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129(4):585–596PubMedPubMedCentralCrossRef
47.
Shirahata M, Ono T, Stichel D et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136(1):153–166PubMedCrossRef
48.
Reuss DE, Mamatjan Y, Schrimpf D et al (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129(6):867–873PubMedPubMedCentralCrossRef
49.
Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718PubMedCrossRef
50.
Cimino PJ, Zager M, McFerrin L et al (2017) Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun 5(1):39PubMedPubMedCentralCrossRef
51.
Korshunov A, Casalini B, Chavez L et al (2019) Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol 45(2):108–118
52.
Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508PubMedPubMedCentralCrossRef
53.
Reuss DE, Kratz A, Sahm F et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130(3):407–417PubMedCrossRef
54.
von Deimling A, Ono T, Shirahata M, Louis DN (2018) Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing. Semin Neurol 38(1):19–23CrossRef
55.
Louis DN, von Deimling A (2017) Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zulch, the WHO… and Shakespeare. Acta Neuropathol 134(4):517–520PubMedCrossRef
56.
Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134(6):957–959PubMedCrossRef
57.
Hasselblatt M, Jaber M, Reuss D et al (2018) Diffuse astrocytoma, IDH-wildtype: a dissolving diagnosis. J Neuropathol Exp Neurol 77(6):422–425PubMedCrossRef
58.
Cohen A, Sato M, Aldape K et al (2015) DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun 3:34PubMedPubMedCentralCrossRef
59.
60.
Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129(5):679–693PubMedCrossRef
61.
Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136(5):793–803PubMedCrossRef
62.
Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110(15):6021–6026PubMedCrossRefPubMedCentral
63.
Killela PJ, Pirozzi CJ, Healy P et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5(6):1515–1525PubMedPubMedCentralCrossRef
64.
Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126(2):267–276PubMedCrossRef
65.
Arita H, Narita Y, Takami H et al (2013) TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol 126(6):939–941PubMedCrossRef
66.
Huang DS, Wang Z, He XJ et al (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51(8):969–976PubMedPubMedCentralCrossRef
67.
Labussiere M, Di Stefano AL, Gleize V et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111(10):2024–2032PubMedPubMedCentralCrossRef
68.
69.
Szerlip NJ, Pedraza A, Chakravarty D et al (2012) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 109(8):3041–3046PubMedPubMedCentralCrossRef
70.
71.
72.
Appin CL, Brat DJ (2015) Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. Adv Anat Pathol 22(1):50–58PubMedCrossRef
73.
Louis DN, Aldape K, Brat DJ et al (2017) Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133(1):1–3PubMedCrossRef
74.
Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 136(5):805–810PubMedPubMedCentralCrossRef
75.
Korshunov A, Ryzhova M, Hovestadt V et al (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129(5):669–678PubMedCrossRef
76.
Tanboon J, Williams EA, Louis DN (2016) The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol 75(1):4–18PubMedCrossRef
77.
Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231PubMedCrossRef
78.
Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–447PubMedPubMedCentralCrossRef
79.
Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437PubMedCrossRef
80.
Gessi M, Gielen GH, Hammes J et al (2013) H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neurooncol 112(1):67–72PubMedCrossRef
81.
Korshunov A, Capper D, Reuss D et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131(1):137–146PubMedCrossRef
82.
Neumann JE, Dorostkar MM, Korshunov A et al (2016) Distinct histomorphology in molecular subgroups of glioblastomas in young patients. J Neuropathol Exp Neurol 75(5):408–414PubMedCrossRef
83.
Haque F, Varlet P, Puntonet J et al (2017) Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathol Commun 5(1):45PubMedPubMedCentralCrossRef
84.
Ichimura K, Narita Y, Hawkins CE (2015) Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):789–808PubMedCrossRef
85.
86.
Solomon DA, Wood MD, Tihan T et al (2016) Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26(5):569–580PubMedCrossRef
87.
88.
Kleinschmidt-DeMasters BK, Mulcahy Levy JM (2018) H3 K27M-mutant gliomas in adults vs children share similar histological features and adverse prognosis. Clin Neuropathol 37(2):53–63PubMedPubMedCentralCrossRef
89.
Louis DN, Giannini C, Capper D et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135(4):639–642PubMedCrossRef
90.
Bechet D, Gielen GG, Korshunov A et al (2014) Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 128(5):733–741PubMedPubMedCentralCrossRef
91.
Venneti S, Santi M, Felicella MM et al (2014) A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol 128(5):743–753PubMedPubMedCentralCrossRef
92.
Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124(5):615–625PubMedCrossRef
93.
Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3(7):709–722PubMedPubMedCentralCrossRef
94.
Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133(6):1001–1016PubMedPubMedCentralCrossRef
Metadata
Title
The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline
Authors
José E. Velázquez Vega
Daniel J. Brat
Timothy C. Ryken
Jeffrey J. Olson
Publication date
01-11-2020
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03616-3

Other articles of this Issue 2/2020

Journal of Neuro-Oncology 2/2020 Go to the issue

Topic Review

Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma

Introduction and Methods

Congress of neurological surgeons systematic review and evidence-based clinical practice parameter guidelines for the treatment of adults with newly diagnosed glioblastoma: Introduction and Methods

Topic Review

Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update

Endorsement

AANS/CNS Endorsement

Topic Review

The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update

Topic Review

The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update